Literature DB >> 17314423

Histopathological study on experimental endophthalmitis induced by bloodstream infection with Candida albicans.

Junko Omuta1, Katsuhisa Uchida, Hideyo Yamaguchi, Kazutoshi Shibuya.   

Abstract

To investigate the details of the pathophysiology of endogenous fungal endophthalmitis (EFE), we performed sequential histological and ophthalmoscopic examination on a rabbit model comparing immunocompromised EFE developed using a steroid with an immunocompetent one intravenously inoculated with Candida albicans. The ophthalmoscopic examination and histological analysis of the retina in both groups demonstrated that lesions appear on the equator of the eyeball and then spread toward the posterior pole. It has been speculated that, because of the unique innate vasculature system of the equator, there is a sudden, decrease of shear stress in rheologically, resulting in adhesion of yeast cells to the endothelial cells. Histological examination revealed that the degree of polymorphonuclear leukocyte (PMN) infiltration was equivalent in the two groups. However, the appearance of PMN was delayed and the number of fungi was higher in the state of hyphae and/or pseudohyphae in the steroid-treated group. Furthermore, the eyeball was found to be the second earliest organ involved in candidemia. Our results indicate that ophthalmic examination is useful to monitor the development and systemic involvement of endophthalmitis in patients with candidemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314423

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  8 in total

1.  Bilateral choroiditis as the only sign of persistent Mycobacterium intracellulare infection following haematogenous spread in an immunocompromised patient.

Authors:  Alessandro Invernizzi; Davide Ricaboni; Marco Franzetti; Giovanni Staurenghi; Peter McCluskey; Fabio Franzetti
Journal:  Infection       Date:  2017-12-09       Impact factor: 3.553

Review 2.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

3.  Endophthalmitis: A review of recent trends.

Authors:  Janice R Safneck
Journal:  Saudi J Ophthalmol       Date:  2012-03-03

4.  Evaluation of Susceptibility and Innate Immune Response in C57BL/6 and BALB/c Mice During Candida albicans Endophthalmitis.

Authors:  Bruce G Rottmann; Pawan Kumar Singh; Sneha Singh; Sanjay G Revankar; Pranatharthi H Chandrasekar; Ashok Kumar
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-09-01       Impact factor: 4.799

5.  Endogenous Fungal Endophthalmitis in a Patient Admitted to Intensive Care and Treated with Systemic Steroid for COVID-19

Authors:  Sema Tamer Kaderli; Aylin Karalezli; Burak Ekrem Çitil; Ali Osman Saatci
Journal:  Turk J Ophthalmol       Date:  2022-04-28

6.  Fatal peripheral candidal suppurative thrombophlebitis in a postoperative patient.

Authors:  Suk-Kyung Hong; So-Hyun Nam; Hee Cheol Kim
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

7.  Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Authors:  J L Livermore; T W Felton; J Abbott; A Sharp; J Goodwin; L Gregson; P A Warn; S J Howard; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

8.  Differences in Ocular Complications Between Candida albicans and Non-albicans Candida Infection Analyzed by Epidemiology and a Mouse Ocular Candidiasis Model.

Authors:  Masahiro Abe; Yuki Kinjo; Keigo Ueno; Shogo Takatsuka; Shigeki Nakamura; Sho Ogura; Muneyoshi Kimura; Hideki Araoka; Sota Sadamoto; Minoru Shinozaki; Kazutoshi Shibuya; Akiko Yoneyama; Mitsuo Kaku; Yoshitsugu Miyazaki
Journal:  Front Microbiol       Date:  2018-10-17       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.